Huons Group Successfully Hosts Launch Symposium for Botulinum Toxin 'Hutox' in China
AI번역
  • 영어

이 기사 AI가 핵심만 딱!
애니메이션 이미지
  • 등록 2026-07-20 오전 10:03:02

    수정 2026-07-20 오전 10:03:02

[NA Eun-kyung, Edaily Reporter] On the 16th, the 'Hutox Launch Symposium' was held at the JW Marriott Hotel in Hangzhou, Zhejiang Province, China. Chief Director of Cellinique Clinic, Dr. Chris Gunwoo Kim, delivers his lecture during the event.

Huons Group is accelerating its entry into the Chinese market with its botulinum toxin product, 'Hutox'.

On the 16th, the 'Hutox Launch Symposium' was held at the JW Marriott Hotel in Hangzhou, Zhejiang Province, China. Chief Director of Cellinique Clinic, Dr. Chris Gunwoo Kim, delivers his lecture during the event.
On the 16th, the 'Hutox Launch Symposium' was held at the JW Marriott Hotel in Hangzhou, Zhejiang Province, China. Chief Director of Cellinique Clinic, Dr. Chris Gunwoo Kim, delivers his lecture during the event.


Huons Group affiliates Humedix and Huons BioPharma announced on the 20th the "Hutox Launch Symposium" was successfully held on the 16th at the JW Marriott Hotel in Hangzhou, Zhejiang Province, China.

The symposium was hosted by Huons BioPharma's local Chinese partner, IMeik Technology (hereafter IMeik). The event featured the official launch announcement of the botulinum toxin product 'Hutox' in China alongside an academic exchange program.

Through this symposium, Humedix and Huons BioPharma aimed to expand broaden touchpoints with local Chinese medical professionals and industry stakeholders, while boosting the global brand awareness of Hutox.

During the event, Dr. Chris Gunwoo Kim, Chief Director of Cellinique Clinic, participated as a guest speaker to deliver a lecture on Hutox. Dr. Kim shared global trends in botulinum toxin utilization, practical clinical applications, and operational know-how for administering the product.

Hutox is an aesthetic and therapeutic pharmaceutical product with botulinum toxin as its active ingredient. It is primarily used for the improvement of glabellar lines and crow's feet.

In 2022, IMeik secured exclusive import and distribution rights for Huons BioPharma's botulinum toxin products in the Greater China region (including Macau and Hong Kong). Following this, IMeik obtained marketing authorization for Hutox from China's National Medical Products Administration (NMPA) last January.

For this launch event, Humedix leveraged its extensive network of Korean medical professionals to support the invitation of the speaker and streamline academic communications.

An official from Huons Group stated, "This Hutox Launch Symposium was a meaningful opportunity to introduce the global applications and academic value of Hutox to local Chinese medical professionals and industry experts. Moving forward, we will continue to drive diverse academic and marketing initiatives to strengthen the brand competitiveness of Hutox in the global market."

이 기사 AI가 핵심만 딱!
애니메이션 이미지

이데일리
추천 뉴스by Taboola

당신을 위한
맞춤 뉴스by Dable

소셜 댓글

많이 본 뉴스

바이오 투자 길라잡이 팜이데일리

왼쪽 오른쪽

MICE 최신정보를 한눈에 TheBeLT

왼쪽 오른쪽

재미에 지식을 더하다 영상+

왼쪽 오른쪽

두근두근 핫포토

  • 독보적 비주얼
  • 현무·윤아 팔짱
  • 멧 데이먼 딸
  • 골프 브이~
왼쪽 오른쪽
  • 04517 서울시 중구 통일로 92 케이지타워 18F, 19F 이데일리
  • 대표전화 02-3772-0114
  • 이메일 webmaster@edaily.co.kr
  • 사업자번호 107-81-75795
  • 등록번호 서울 아 00090
  • 등록일자 2005.10.25
  • 회장 곽재선
  • 발행·편집인 이익원
  • 청소년보호책임자 임경진